Halozyme Therapeutics HALO
NASDAQ HALO
$102.98 +0.06 (+0.06%)
At close: Nov 10, 2026 · 4:00 PM EST

Halozyme Therapeutics (HALO) Capital Leases (2012 - 2013)

Updated

Halozyme Therapeutics (HALO) recorded Capital Leases of $2.55 million in Q3 2013, up 21.4% from the prior quarter.

Analysis

Halozyme Therapeutics (HALO) Capital Leases (2012 - 2013) Analysis & Trends

At the end of FY2012, Halozyme Therapeutics reported Capital Leases of $1.45 million.

  • Per Business Quant, the preceding three quarters came in at $2.1 million (Q2 2013), $1.45 million (Q1 2013) and $1.45 million (Q4 2012).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn
5 Novartis Ag 311.58 Bn 285.16 Bn -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn
10 Halozyme Therapeutics 11.73 Bn 9.97 Bn 410.50 Mn
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2013 2.55 Mn
Jun 30, 2013 2.10 Mn
Mar 31, 2013 1.45 Mn
Dec 31, 2012 1.45 Mn
API Access

Halozyme Therapeutics Capital Leases API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=capital-leases&ticker=HALO&period=max&api_key=YOUR_API_KEY